Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Matt O'Brien reiterates AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $60 to $70.
Piper Sandler analyst Matt O'Brien reiterates AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $60 to $70.